Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A case of IgG4-related autoimmune disease with multiple organ involvement.
Nakamura H, Wada H, Origuchi T, Kawakami A, Taura N, Aramaki T, Fujikawa K, Iwanaga N, Izumi Y, Aratake K, Ida H, Taguchi T, Irie J, Akiyama M, Mizokami A, Tsutsumi T, Eguchi K. Nakamura H, et al. Among authors: mizokami a. Scand J Rheumatol. 2006 Jan-Feb;35(1):69-71. doi: 10.1080/03009740500499484. Scand J Rheumatol. 2006. PMID: 16467047
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K. Iwamoto N, et al. Among authors: mizokami a. Mod Rheumatol. 2009;19(5):488-92. doi: 10.1007/s10165-009-0187-8. Epub 2009 Jul 4. Mod Rheumatol. 2009. PMID: 19578932
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M, Arima K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Furuyama M, Matsuoka N, Ueki Y, Ida H, Origuchi T, Aoyagi K, Eguchi K. Aramaki T, et al. Among authors: mizokami a. Mod Rheumatol. 2009;19(6):652-6. doi: 10.1007/s10165-009-0216-7. Mod Rheumatol. 2009. PMID: 19787419
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K. Origuchi T, et al. Among authors: mizokami a. Mod Rheumatol. 2011 Jun;21(3):244-50. doi: 10.1007/s10165-010-0384-5. Epub 2010 Dec 29. Mod Rheumatol. 2011. PMID: 21188454
Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K. Kawashiri SY, et al. Among authors: mizokami a. Mod Rheumatol. 2011 Aug;21(4):365-9. doi: 10.1007/s10165-010-0402-7. Epub 2011 Jan 13. Mod Rheumatol. 2011. PMID: 21229375
In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ueki Y, Migita K, Mizokami A, Aoyagi K, Eguchi K. Kawashiri SY, et al. Among authors: mizokami a. Mod Rheumatol. 2011 Aug;21(4):370-4. doi: 10.1007/s10165-010-0409-0. Epub 2011 Jan 15. Mod Rheumatol. 2011. PMID: 21240618
498 results